Physician profile
Travis Chase
NPI 1508255068
$1,059.65
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.13 · 2022: $471 · 2023: $378 · 2024: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $496.12 | 2022-2024 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $143.31 | 2021-2023 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $67.07 | 2021-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.84 | 2022 | |
| Alkermes, INC. | $57.43 | 2023 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $41.70 | 2022 | |
| Bausch Health US, LLC | $35.44 | 2022 | |
| Idorsia Pharmaceuticals US INC | $29.62 | 2023 | Quviviq |
| Lundbeck LLC | $28.93 | 2022 | |
| Sunovion Pharmaceuticals INC. | $28.81 | 2022 | |
| Neurocrine Biosciences, INC. | $27.20 | 2022 | |
| Supernus Pharmaceuticals, INC. | $26.24 | 2022 | |
| Abbvie INC. | $13.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Chase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.